Compounds and their effects on feeding behaviour

Patent metadata

Field	Value
Publication number	US-9944687-B2
Application number	US-201114128081-A
Country	US
Kind code	B2
Filing date	Jul 4, 2011
Priority date	Jul 4, 2011
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

Peptide containing sequence from both the GLP-1 peptide and glucagon peptide, compositions comprising said peptides and methods of using said peptides for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as obesity or diabetes, are provided.

First claim

The invention claimed is:

1. A compound that is a peptide having a sequence represented by formula I
A-B  (I)

wherein A represents a region of the peptide having a sequence His1-Xaa2-Gln3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Xaa10-Ser11-Xaa12-Tyr13-Leu14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa21-Phe22-Xaa23-Xaa24-Xaa25-Leu26-Xaa27-Xaa28-Xaa29;
wherein B is a region of the peptide having a sequence selected from
His30-His31; and
His30-His31-HN 2 ,

wherein —NH 2 represents C-terminal amidation of the peptide;
wherein Xaa2 is Ser2, or an α-aminoisobutyric acid residue;
Xaa10 is Tyr10 or Val10;
Xaa12 is Lys12, His12, or Arg12;
Xaa15 is Asp15, Asn15, or Glu15;
Xaa16 is Ser16, Glu16, or Gly16;
Xaa17 is Glu17, Gln17, Arg17, Ser17 or Lys17;
Xaa18 is Ala18, Ile18, or Arg18;
Xaa19 is Ala19 or Val19;
Xaa20 is Lys20, Arg20, His20 or Gln20;
Xaa21 is Glu21, Tyr21, Leu21, or His21;
Xaa23 is Ile23 or Val23;
Xaa24 is Glu24 or Gln24;
Xaa25 is Trp25, His25, Lys25, Tyr25 or Leu25;
Xaa27 is Val27, Lys27, or Leu27;
Xaa28 is Lys28 or Asn28;
Xaa29 is Gly29, Thr29, or Arg29;

or a salt and/or solvate of said compound,
with the proviso that at least one of the following criteria apply:
an α-aminoisobutyric acid residue is present at position 2 of the peptide sequence;
Val10 is present at position 10 of the peptide sequence;
Ser17 is present at position 17 of the peptide sequence;
Ile18 is present at position 18 of the peptide sequence;
His25 is present at position 25 of the peptide sequence;
Lys25 is present at position 25 of the peptide sequence;
Leu27 is present at position 27 of the peptide sequence; and
Val 27 is present at position 27 of the peptide sequence.

2. A compound as claimed in claim 1 wherein:
Xaa2 is Ser2 or an α-aminoisobutyric acid residue;
Xaa10 is Tyr10 or Val10;
Xaa12 is Lys12 or His12;
Xaa15 is Asp15 or Glu15;
Xaa16 is Ser16, Glu16 or Gly16;
Xaa17 is Glu17, Gln17, Arg17, Ser17 or Lys17;
Xaa18 to Xaa20 is Ala18-Val19-Arg20, Ala18-Val19-Lys20 or Ala18-Val19-His20;
Xaa21 is Glu21, Tyr21, Leu21 or His21;
Xaa23 is Ile23 or Val23;
Xaa25 is Trp25 or Lys25;
Xaa28 is Lys28 or Asn28; and
Xaa29 is Gly29 or Thr29;

wherein B is a region of the peptide having a sequence selected from:
His30-His31 and His30-His31-NH 2 .

3. A compound as claimed in claim 2 , wherein
Xaa2 is Ser2;
Xaa10 is Tyr10;
Xaa16 is Ser16 or Glu16;
Xaa17 is Glu17 or Gln17;
Xaa21 is Leu21 or His21;
Xaa23 is Ile23;
Xaa25 is Trp25;
Xaa27 is Lys27, Leu27 or Val27;
Xaa28 is Asn28;

wherein B is a region of the peptide having a sequence selected from His30-His31 or His30-His31-NH 2 .

4. A compound as claimed in claim 1 , wherein B is a region of the peptide having a sequence which is His30-His31.

5. A pharmaceutical composition comprising a compound as claimed in claim 1 together with a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.

6. The pharmaceutical composition as claimed in claim 5 wherein said compound comprises at least 3 His residues, and wherein the composition has a pH of less than 5.0 prior to administration and wherein the composition comprises at least one zinc ion for every 4 molecules of peptide.

7. A method of treating or preventing a disease or disorder or other non-desired physiological state in a subject comprising administering to the subject a compound as claimed in claim 1 .

8. The method as claimed in claim 7 , wherein the method is a method of treating obesity or diabetes in a subject in need thereof, a method of reducing appetite in a subject, a method of reducing food intake in a subject, a method of reducing calorie intake in a subject, a method of increasing the energy expenditure of a subject, a method of enhancing insulin release in a subject, a method of improving carbohydrate tolerance in a subject, a method of improving carbohydrate metabolism in a subject, a method of cardiac protection in a subject following myocardial infarction, a method of neuroprotection in a subject having cerebral ischemia and/or a method of neuroprotection in a subject having or diagnosed as being at risk of a chronic neurodegenerative disease.

9. The method of claim 8 wherein the subject is overweight.

10. The method of claim 8 wherein the compound is administered parentally.

11. The method of claim 8 wherein the compound is administered subcutaneously, intravenously, intramuscularly, intranasally, transdermally or sublingually.

12. A method of treating or preventing a disease or disorder or other non-desired physiological state in a subject comprising administering to the subject a pharmaceutical composition as claimed in claim 5 .

13. The method as claimed in claim 12 , wherein the method is a method of treating obesity or diabetes in a subject in need thereof, a method of reducing appetite in a subject, a method of reducing food intake in a subject, a method of reducing calorie intake in a subject, a method of increasing the energy expenditure of a subject, a method of enhancing insulin release in a subject, a method of improving carbohydrate tolerance in a subject, a method of improving carbohydrate metabolism in a subject, a method of cardiac protection in a subject following myocardial infarction, a method of neuroprotection in a subject having cerebral ischemia and/or a method of neuroprotection in a subject having or diagnosed as being at risk of a chronic neurodegenerative disease.

14. The method as claimed in claim 13 wherein the subject is overweight, obese and/or diabetic.

15. The method as claimed in claim 12 , wherein the pharmaceutical composition is administered subcutaneously.

Assignees

• Bloom Stephen Robert
• Imperial Innovations Ltd

Inventors

• Bloom Stephen Robert

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title